WordNet

the scar left following inoculation with a vaccine
preventing or contributing to the prevention of disease; "preventive medicine"; "vaccines are prophylactic"; "a prophylactic drug" (同)preventative, prophylactic
remedy that prevents or slows the course of an illness or disease; "the doctor recommended several preventatives" (同)preventative, prophylactic
tending to prevent or hinder (同)preventative
taking a vaccine as a precaution against contracting a disease (同)vaccination

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. B型肝炎ウイルス感染の疫学、伝染、および予防 epidemiology transmission and prevention of hepatitis b virus infection
2. 尿路感染症における細菌付着およびその他の病原因子 bacterial adherence and other virulence factors for urinary tract infection
3. 狂犬病の治療 treatment of rabies
4. 結核の皮膚症状 cutaneous manifestations of tuberculosis
5. 小児における非結核性抗酸菌の皮膚および軟部組織感染症の概要 overview of nontuberculous mycobacterial skin and soft tissue infections in children

Blank PR, Schwenkglenks M, Sardos CS, Patris J, Szucs TD.SourceInstitute of Pharmaceutical Medicine, University of Basel, Klingelbergstrasse 61, 4056 Basel, Switzerland; Institute of Social and Preventive Medicine, University of Zurich, Hirschengraben 84, 8001 Zurich, Switzerland. Electronic address: patricia.blank@ifspm.uzh.ch.
Vaccine.Vaccine.2013 Jun 12;31(27):2862-7. doi: 10.1016/j.vaccine.2013.04.039. Epub 2013 Apr 28.
Time from registration to population access to new vaccines can take considerable time in European countries. Reasons might be found in the regulatory framework, decision-making processes or the assessment of vaccines by evaluating bodies. The aim of this study was to determine whether some decision
PMID 23632307

Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines.

Rowland R, O'Hara GA, Hamill M, Poulton ID, Donaldson H, Dinsmore L, James T, Barnes E, Klenerman P, Gilbert SC, Hill AV, Shine B, McShane H.SourceThe Jenner Institute; University of Oxford; Oxford, UK.
Human vaccines & immunotherapeutics.Hum Vaccin Immunother.2013 Jun 3;9(8). [Epub ahead of print]
This was a retrospective study to determine the validity of institutional reference intervals for interpreting biochemistry and hematology results in healthy adults in the context of clinical trials of preventive vaccines. An example population of 974 healthy adults participating in clinical trials
PMID 23733037

Evaluation of RevA, a Fibronectin-Binding Protein of Borrelia burgdorferi, as a Potential Vaccine Candidate for Lyme Disease.

Floden AM, Gonzalez T, Gaultney RA, Brissette CA.SourceDepartment of Microbiology and Immunology, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota, USA.
Clinical and vaccine immunology : CVI.Clin Vaccine Immunol.2013 Jun;20(6):892-9. doi: 10.1128/CVI.00758-12. Epub 2013 Apr 17.
Previous studies indicated that the Lyme disease spirochete Borrelia burgdorferi expresses the RevA outer surface protein during mammalian infection. As an adhesin that promotes bacterial interaction with fibronectin, RevA appears to be a good target for preventive therapies. RevA proteins are highl
PMID 23595502